Acumen Pharmaceuticals

Update in progress

ABOS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharma focused on targeted therapies for Alzheimer's disease. Its lead candidate, sabirnetug (ACU193), targets toxic soluble amyloid beta oligomers and is in Phase 2 (ALTITUDE-AD). The company partners with Halozyme for a subcutaneous formulation and with JCR Pharmaceuticals for enhanced brain delivery of Aβ oligomer therapies. Incorporated in 1996, it is based in Newton, Massachusetts.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.36; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.13; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive